Janus kinase inhibitors and biosimilars for rheumatoid arthritis: final policy recommendations

Janus kinase inhibitors and biosimilars for rheumatoid arthritis: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, January 9, 2020
Language(s):
English
Format:
Text
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Janus Kinase Inhibitors
United States
Genre(s):
Technical Report
Abstract:
The following policy recommendations reflect the main themes and points made during the Policy Roundtable discussion at the December 9, 2019 CTAF public meeting on the use of Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA). At the meeting, ICER presented the findings of its revised report on these treatments and the CTAF voting panel deliberated on key questions related to their comparative clinical effectiveness, potential other benefits and contextual considerations, and long-term value for money at current prices. Following the votes, ICER convened a Policy Roundtable of two patients, two clinical experts, two payers, and two representatives from a pharmaceutical manufacturer to discuss how best to apply the evidence and votes to real-world practice and policy. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (9 pages))
NLM Unique ID:
9918402188706676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918402188706676